Delving into the Latest Updates on Advenchen Laboratories Nanjing Ltd. with Synapse

Overview

Tags

Neoplasms

Urogenital Diseases

Digestive System Disorders

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Endocrinology and Metabolic Disease	4
Hemic and Lymphatic Diseases	2
Immune System Diseases	2

Top 5 Drug Type	Count

Small molecule drug	6

Top 5 Target	Count

Aurora B x FGFRs x VEGFR	1
FGFR1 x FGFR2 x VEGFR1 x VEGFR2 x VEGFR3	1
PI3Kα x mTOR	1
PI3Ks x mTOR	1
c-Met(Hepatocyte growth factor receptor)	1

Primary objective To evaluate the preliminary efficacy of AL2846 capsules in patients with iodine-refractory differentiated thyroid cancer who have failed previous TKI treatment. Secondary objective To evaluate the safety of AL2846 capsules in patients with iodine-refractory differentiated thyroid cancer who have failed previous TKI treatment.

Start Date16 Feb 2023

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

[+1]

NCT05486598

/ Unknown statusPhase 1

A Phase IB Clinical Trial to Evaluate the Effect of High-fat Diet on Pharmacokinetics of AL8326 Tablets in Chinese Healthy Adult Subjects

Main study objective: the pharmacokinetic effects of high-fat diet on AL8326 after oral administration of AL8326 tablets in Chinese healthy adult subjects.
Secondary study objectives: safety and tolerability of a single oral dose of AL8326 tablets in healthy subjects

Start Date21 Jun 2022

Sponsor / Collaborator

Advenchen Laboratories Nanjing Ltd.

100 Clinical Results associated with Advenchen Laboratories Nanjing Ltd.

Login to view more data

0 Patents (Medical) associated with Advenchen Laboratories Nanjing Ltd.

Login to view more data

100 Deals associated with Advenchen Laboratories Nanjing Ltd.

Login to view more data

100 Translational Medicine associated with Advenchen Laboratories Nanjing Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

Phase 1

Phase 3

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Anlotinib Dihydrochloride ( FGFRs x PDGFRs x Tyrosine kinase x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit )	Primary peritoneal carcinoma More	Phase 3
Vilzemetkib ( c-Met )	Advanced Malignant Solid Neoplasm More	Phase 2
AL-8326 ( Aurora B x FGFRs x VEGFR )	Advanced Malignant Solid Neoplasm More	Phase 1
AL58805 ( PI3Ks x mTOR )	Head and Neck Neoplasms More	Phase 1
AL-58922 ( PI3Kα x mTOR )	Neoplasms More	Preclinical